Cell and Gene Therapy (CGT) is redefining the boundaries of human disease treatment. As one of the world's most active regions in CGT R&D pipelines, richest in clinical resources, and most innovative in policy, China is contributing "China Solutions" and "China Wisdom" to global CGT development through its unique institutional advantages, research strength, and industrial ecosystem, becoming an indispensable force in the global CGT innovation landscape.
In 2026, China's CGT regulatory framework undergoes a systemic transformation. The Regulations on the Administration of Clinical Research and Clinical Translation Application of Biomedical New Technologies (known in the industry as "Decree 818") and the Implementation Regulations of the Drug Administration Law of the People's Republic of China (known as "Decree 828") come into effect successively, jointly establishing a new regulatory landscape for cell and gene therapy. The concentrated release of policy dividends is accelerating China's emergence as an important birthplace of global CGT innovation assets.
On September 19–20, 2026, the China Symposium on Cell and Gene Therapy (CSGCT) will reopen at the Beijing Zhongguancun National Independent Innovation Demonstration Zone Exhibition and Trading Center - Convention Center. As the most internationally influential CGT event in the Asia-Pacific region, CSGCT closely collaborates with ASGCT (American Society of Gene & Cell Therapy), leveraging top-tier global CGT resources to bring together outstanding regulatory bodies, scientists, innovative drug companies, clinical experts, supply chain enterprises, large pharmaceutical companies, and investment institutions from around the world. This year's symposium will feature 1 main forum + 23 high-end sub-forums, welcoming 300+ leading domestic and international experts, 3,000+ participants, and 500+ investment institutions. It will deliver the most cutting-edge regulatory and market access information, clinical breakthroughs, scientific research advances, technologies and applications, high-quality collaboration projects, and overseas investment & BD matchmaking opportunities, building a platform for deep exchange and cooperation between China's cell and gene therapy industry and the global ecosystem.
Conference Name: 2026 China Symposium on Cell and Gene Therapy (CSGCT)
Dates: September 19–20, 2026 (Saturday–Sunday)
Venue: Zhongguancun National Independent Innovation Demonstration Zone Exhibition and Trading Center - Convention Center (Beijing)
Guiding Organizations: Beijing Municipal Science & Technology Commission, Administrative Committee of Zhongguancun Science Park, Haidian District People's Government of Beijing
Hosts: Zhongguancun Science City Management Committee, CSGCT China Cell and Gene Therapy Alliance
Organizers: Beijing Medical & Health Science and Technology Development Center, HIEA Medical Innovation Ecosystem Alliance, VBData
Limited-time free tickets – scan code to register now
The 2026 CSGCT will feature 1 main forum, 23 sub-forums, 1 awards gala, 2 roadshows, and 5 conference events.
Internationalization: Global innovation forces gather
The conference brings together the most foundational and influential figures in global cell and gene therapy, including pioneers who have defined the direction of the industry such as Jude Samulski, Carl June, Frank Graham, Mark Kay, Guangping Gao, Feng Zhang, Terence Flotte, Barry Byrne, Ana Hidalgo-Simon; core executives from leading international companies such as Capstan, Arbor Biotechnologies, Voyager Therapeutics, Eli Lilly; and权威 experts from Stanford, UNC, UMich, McMaster, HKU and other academic institutions.
Participants cover CGT R&D hubs of the United States and Europe, extending to innovation hubs in Australia, Japan, Singapore and other Asia-Pacific regions, as well as connecting with emerging markets such as Indonesia and Malaysia, and industrial and capital forces from the UAE, Saudi Arabia and beyond. They come with clear collaboration needs – to connect with China's advanced pipelines, clinical resources, and industrialization capabilities, and to explore cross-border BD and investment opportunities.
The 2026 CSGCT will feature sub-forums on "Synergistic Evolution of the Global CGT Alliance Network", "China's IIT as a New Fulcrum for Global Standards", "International Innovation and Collaboration in Southeast Asian Cell and Gene Therapy", as well as special events such as the "China IIT Resource Matchmaking Session" and "CGT Overseas BD Resource Matchmaking Session".
Regulation & Clinical: Authoritative Interpretation and In-depth Exchange
With the continuous improvement of China's CGT regulatory system in 2026, the CSGCT will leverage dual resource advantages in pharmaceuticals and biomedical new technologies to offer participants:
Authoritative policy interpretation: Latest regulatory practices, IND/BLA submission and accelerated pathways
Resource matchmaking platform: Connecting top-tier clinical research institutions, PI resources, and patient networks nationwide
International collaboration window: Facilitating precise matching of overseas innovation projects with China's clinical resources and regulatory pathways
Authoritative regulatory and review experts will interpret the latest review criteria and submission strategies onsite. Leading clinical PIs from Peking University Third Hospital, Peking University Cancer Hospital, Peking Union Medical College Hospital, Wuhan Union Hospital, Cancer Hospital of the Chinese Academy of Medical Sciences, Beijing Children's Hospital, 301 Hospital, and others will share the latest clinical trial data, key clinical design approaches, and product selection logic.
The 2026 CSGCT will feature sub-forums on "Global Clinical Applications and Breakthroughs of CGT in Cardiovascular and Metabolic Diseases", "Global Clinical Applications and Breakthroughs of CGT in CNS and Oncology", "Global Clinical Applications and Breakthroughs of CGT in Anti-Aging and Longevity", as well as special events including a closed-door session on "Advanced Therapy Drugs and Clinical New Technology Policy Application & Interpretation", the "China IIT Resource Matchmaking Session", and the "In-depth Tour of China's Top Tertiary Hospitals' Biomedical New Technologies".
Full Industry Chain: Gathering of Key Decision-Makers
Regulatory agencies, clinical PIs, major domestic and international pharmaceutical companies, innovative drug companies, research institutions, supply chain and CXO enterprises, investment institutions, and patient organizations gather to bring multi-perspective cutting-edge insights and exchanges. Over 70% are at the decision-maker level, providing direct access to key decision-makers from R&D initiation to process selection and commercialization.
Full Spectrum: Comprehensive Coverage of Cutting-Edge Technologies
Full coverage of technology routes, with sub-forums on gene therapy, gene editing, immune cells, stem cells, exosomes, iPSC, in vivo cell therapy, nucleic acid drugs, oncolytic viruses, cancer vaccines, and other major technology branches, inviting leading companies from each track to share industrialization progress. Sub-forums also address cross-cutting topics such as investment and financing, clinical translation, delivery technologies, regulation, CMC, and AI empowerment.
Precision Targeting: 1-on-1 Directed Meetings
The conference will set up dedicated matchmaking spaces and provide pre-conference 1-on-1 directed appointment services to help you lock in target partners in advance and connect efficiently onsite, ensuring every interaction reaches decision-makers precisely and helps enterprises establish effective contact with target audiences. Meanwhile, ample networking time is reserved in the agenda, including forum interactions, coffee breaks, closed-door invitation-only luncheons, dinner exchanges, cocktail receptions, and other high-quality social settings.
In 2025, the CSGCT received extensive coverage from nearly 60 major national media platforms, including Xinhuanet, People's Daily Health Client, Guangming Daily, China Daily, Beijing Daily, Securities Times, 21st Century Business Herald, PharmCube, Tongxieyi, and others, generating large-scale dissemination across the internet. A total of over 200 reports were published, precisely reaching more than 400,000 professionals and achieving over 3 million media impressions 。
05
Closing Remarks
Global cell and gene therapy looks to China; China's cell and gene therapy looks to CSGCT!
In 2026, China has become an important choice for global CGT companies to conduct clinical research and validate technology platforms. CSGCT serves as a core platform connecting China with the global CGT ecosystem, providing domestic and overseas enterprises with one‑stop services for policy interpretation, clinical resource matching, and BD collaboration.
We sincerely invite scientists, clinical experts, entrepreneurs, investors, and industry partners in the global CGT field to gather in Beijing on September 19–20, 2026, to jointly explore cutting-edge topics in CGT development, connect global innovation resources, and promote the common progress of the industry.
Limited-time free tickets – scan code to register now
2026 CSGCT, autumn in Beijing – we look forward to seeing you!
For conference sponsorship and participation inquiries, please contact: Ms. Li 18600921680 (Phone/WeChat)
注：嘉宾排名不分先后
CSGCT Alliance Events
2026 ASGCT Direct to Boston – See the Next Logic of CGT Breakthroughs (May 10–16)
About the CSGCT China Cell and Gene Therapy Alliance
Mission and Positioning of the CSGCT Alliance and Conference
Promote the application of GCT technologies in China, with the goal of reducing patient suffering and saving lives
Become a platform for gathering and a connector for collaboration among scientists, physicians, patient organizations, regulatory agencies, enterprises, and investors in China's GCT field
Promote the brand value of China's CGT industry, accelerate deep global integration, and advance the accessibility of innovative therapies
Vision of the CSGCT Alliance and Conference
Drive innovation and translation: Focus on the cell and gene therapy (CGT) field, connecting the entire chain from basic research, technology development, clinical trials, to industrial translation, accelerating the integration of Chinese CGT products, technologies, and services into global markets
Build a collaborative ecosystem: By integrating domestic and international research resources, clinical institutions, enterprises, and capital, establish a multi-dimensional collaboration platform of "government-industry-academia-research-medicine-capital" to help solve common industry challenges (such as financing needs, regulatory communication, supply chain stability, international collaboration, etc.)
渝公网安备 50011202502165号
